sing Hemoperfusion with HA380 Filter to Improve Heart and Liver Transplant Outcomes
Phase 1
- Conditions
- Donors of organs and tissues.Donors of organs and tissues
- Registration Number
- IRCT20220919055992N2
- Lead Sponsor
- Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
eligible for organ donation
have consent and aware of donation
Exclusion Criteria
liver cirrhosis
heart failure
prior heart surgery
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does HA380 hemoperfusion target to improve heart and liver transplant outcomes in IRCT20220919055992N2?
How does HA380 hemoperfusion compare to standard immunosuppressive therapies in reducing post-transplant rejection rates?
Which cytokine or immune cell biomarkers predict response to HA380 hemoperfusion in organ transplant recipients?
What are the potential adverse events associated with HA380 filter use in phase I heart and liver transplant trials?
Are there combination therapies involving HA380 hemoperfusion and anti-inflammatory agents for optimizing graft survival in organ transplants?